SAN Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for SAN from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €89.62 |
| 52 Week High | €110.88 |
| 52 Week Low | €85.07 |
| Beta | 0.48 |
| 1 Month Change | -15.40% |
| 3 Month Change | -6.27% |
| 1 Year Change | 3.64% |
| 3 Year Change | -13.11% |
| 5 Year Change | 3.52% |
| Change since IPO | 115.43% |
Recent News & Updates
Sanofi (EPA:SAN) Is Paying Out A Larger Dividend Than Last Year
Apr 01
Sanofi (EPA:SAN) Is Increasing Its Dividend To €3.92
Mar 18Recent updates
Sanofi (EPA:SAN) Is Paying Out A Larger Dividend Than Last Year
Apr 01Sanofi (EPA:SAN) Is Increasing Its Dividend To €3.92
Mar 18Sanofi's (EPA:SAN) Earnings Offer More Than Meets The Eye
Feb 21Is Sanofi (EPA:SAN) Using Too Much Debt?
Dec 19
Beyfortus And Altuviiio Shine As Calculated Acquisitions And Innovations Fuel Growth
Nov 07 Strong performance in new medicines and Dupixent's market expansion boosts Sanofi's revenue growth and addresses unmet medical needs globally.Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors
Sep 10Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly
Aug 17Shareholder Returns
| SAN | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -6.6% | -6.6% | -1.6% |
| 1Y | 3.6% | 1.3% | -11.1% |
Return vs Industry: SAN exceeded the French Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: SAN exceeded the French Market which returned -11.1% over the past year.
Price Volatility
| SAN volatility | |
|---|---|
| SAN Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.3% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: SAN has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: SAN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 82,878 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
Sanofi Fundamentals Summary
| SAN fundamental statistics | |
|---|---|
| Market cap | €109.70b |
| Earnings (TTM) | €5.50b |
| Revenue (TTM) | €44.29b |
20.0x
P/E Ratio2.5x
P/S RatioIs SAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAN income statement (TTM) | |
|---|---|
| Revenue | €44.29b |
| Cost of Revenue | €13.20b |
| Gross Profit | €31.09b |
| Other Expenses | €25.60b |
| Earnings | €5.50b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 4.49 |
| Gross Margin | 70.21% |
| Net Profit Margin | 12.41% |
| Debt/Equity Ratio | 20.6% |
How did SAN perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield89%
Payout RatioDoes SAN pay a reliable dividends?
See SAN dividend history and benchmarks| Sanofi dividend dates | |
|---|---|
| Ex Dividend Date | May 12 2025 |
| Dividend Pay Date | May 14 2025 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 31 days |
Does SAN pay a reliable dividends?
See SAN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 18:29 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sanofi is covered by 63 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |